Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. That said, here are three stocks under $10 to avoid and some other investments you should consider instead.
Stitch Fix (SFIX)
Share Price: $2.62
One of the original subscription box companies, Stitch Fix (NASDAQ: SFIX) is an online personal styling and fashion service that curates personalized clothing selections for customers.
Why Are We Out on SFIX?
- Sluggish trends in its active clients suggest customers aren’t adopting its solutions as quickly as the company hoped
- Earnings growth underperformed the sector average over the last five years as its EPS grew by just 11.5% annually
- Forecasted free cash flow margin suggests the company will fail to improve its cash conversion over the next year
Stitch Fix’s stock price of $2.62 implies a valuation ratio of 6.8x forward EV-to-EBITDA. If you’re considering SFIX for your portfolio, see our FREE research report to learn more.
Petco (WOOF)
Share Price: $2.17
Historically known for its window displays of pets for sale or adoption, Petco (NASDAQ: WOOF) is a specialty retailer of pet food and supplies as well as a provider of services such as wellness checks and grooming.
Why Do We Pass on WOOF?
- Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations
- Negative returns on capital show that some of its growth strategies have backfired
- High net-debt-to-EBITDA ratio of 6× increases the risk of forced asset sales or dilutive financing if operational performance weakens
At $2.17 per share, Petco trades at 9x forward P/E. To fully understand why you should be careful with WOOF, check out our full research report (it’s free).
Ocular Therapeutix (OCUL)
Share Price: $7.06
Pioneering a drug delivery platform that can eliminate the need for monthly eye injections, Ocular Therapeutix (NASDAQ: OCUL) develops sustained-release treatments for eye diseases using its proprietary ELUTYX bioresorbable hydrogel technology that gradually releases medication.
Why Do We Steer Clear of OCUL?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 7.7% annually over the last two years
- Earnings per share fell by 7.5% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
- 371.3 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
Ocular Therapeutix is trading at $7.06 per share, or 28.6x forward price-to-sales. Dive into our free research report to see why there are better opportunities than OCUL.
Stocks We Like More
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
